-
The feasibility and utility of harnessing digital health to understand clinical trajectories in medication treatment for opioid use disorder: D-TECT study design and methodological considerations.
Marsch LA, Chen C, Adams SR, Asyyed A, Does MB, Hassanpour S, Hichborn E, Jackson-Morris M, Jacobson NC, Jones HK, Kotz D, Lambert-Harris CA, Li Z, McLeman B, Mishra V, Stanger C, Subramaniam G, Wu W, Campbell CI. The feasibility and utility of harnessing digital health to understand clinical trajectories in medication treatment for opioid use disorder: D-TECT study design and methodological considerations. Frontiers in Psychiatry 2022;13:871916.
-
Models for implementing emergency department-initiated buprenorphine with referral for ongoing medication treatment at emergency department discharge in diverse academic centers.
Whiteside LK, D'Onofrio G, Fiellin DA, Edelman J, Richardson L, O'Connor P, Rothman RE, Cowan E, Lyons MS, Fockele CE, Saheed M, Freiermuth C, Punches BE, Guo C, Martel S, Owens PH, Coupet E, Hawk KF. Models for implementing emergency department-initiated buprenorphine with referral for ongoing medication treatment at emergency department discharge in diverse academic centers. Annals of Emergency Medicine 2022;80(5):410-419.
-
Sex differences in weight gain during medication-based treatment for opioid use disorder: A Meta-analysis and retrospective analysis of clinical trial data.
Manza P, Kroll D, McPherson KL, Johnson A, Dennis E, Hu L, Tai B, Volkow ND. Sex differences in weight gain during medication-based treatment for opioid use disorder: A Meta-analysis and retrospective analysis of clinical trial data. Drug and Alcohol Dependence 2022;238:109575.
-
Social determinants of mortality of COVID-19 and opioid overdose in American rural and urban counties.
Zhu Y, Fei Z, Mooney LJ, Huang K, Hser Y. Social determinants of mortality of COVID-19 and opioid overdose in American rural and urban counties. Journal of Addiction Medicine 2022;16(1):e52-e55.
-
Comparison of medical cannabis use reported on a confidential survey vs documented in the electronic health record among primary care patients.
Lapham GT, Matson TE, Carrell DS, Bobb JF, Luce C, Oliver MM, Ghitza UE, Hs C, Browne KC, Binswanger IA, Campbell CI, Saxon AJ, Vandrey R, Schauer GL, Pacula RL, Horberg M, Baily SF, McClure EA, Bradley KA. Comparison of medical cannabis use reported on a confidential survey vs documented in the electronic health record among primary care patients. JAMA Network Open 2022;5(5):e2211677.
-
Co-occurring depression and suicidal ideation in opioid use disorder: Prevalence and response during treatment with buprenorphine-naloxone and injection naltrexone.
Na PJ, Scodes J, Fishman MJ, Rotrosen J, Nunes EV. Co-occurring depression and suicidal ideation in opioid use disorder: Prevalence and response during treatment with buprenorphine-naloxone and injection naltrexone. Journal of Clinical Psychiatry 2022;83(3):21m14140.
-
Safety and efficacy of a digital therapeutic for substance use disorder: secondary analysis of data from a NIDA Clinical Trials Network Study.
Maricich YA, Nunes EV, Campbell ANC, Botbyl JD, Luderer HF. Safety and efficacy of a digital therapeutic for substance use disorder: secondary analysis of data from a NIDA Clinical Trials Network Study. Substance Abuse 2022;43(1):937-942.
-
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Tsui JI, Campbell ANC, Pavlicova M, Choo T, Lee JD, Cook RR, Shulman M, Nunes EV, Rotrosen J. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug and Alcohol Dependence 2022;236:109469.
-
Pain severity and interference and substance use among community pharmacy patients prescribed opioids: A secondary analysis of the PHARMSCREEN study.
Charron E, Okifuji A, Bryan MA, Reese S, Brown JL, Ferguson A, Ghitza UE, Winhusen T, Cochran G. Pain severity and interference and substance use among community pharmacy patients prescribed opioids: A secondary analysis of the PHARMSCREEN study. Journal of Pain 2022;23(8):1448-1459.
-
Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids.
Brown JL, Cochran G, Bryan MA, Charron E, Winhusen TJ. Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids. Substance Abuse 2022;43(1):1110-1115.